These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2568404)

  • 1. In vitro reactivation of rat cortical tryptophan hydroxylase following in vivo inactivation by methylenedioxymethamphetamine.
    Stone DM; Hanson GR; Gibb JW
    J Neurochem; 1989 Aug; 53(2):572-81. PubMed ID: 2568404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine.
    Schmidt CJ; Taylor VL
    Biochem Pharmacol; 1987 Dec; 36(23):4095-102. PubMed ID: 2891359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute inactivation of tryptophan hydroxylase by amphetamine analogs involves the oxidation of sulfhydryl sites.
    Stone DM; Johnson M; Hanson GR; Gibb JW
    Eur J Pharmacol; 1989 Mar; 172(1):93-7. PubMed ID: 2714371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of MK-801 on the decrease in tryptophan hydroxylase induced by methamphetamine and its methylenedioxy analog.
    Johnson M; Hanson GR; Gibb JW
    Eur J Pharmacol; 1989 Jun; 165(2-3):315-8. PubMed ID: 2570704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat.
    Stone DM; Merchant KM; Hanson GR; Gibb JW
    Neuropharmacology; 1987 Dec; 26(12):1677-83. PubMed ID: 2893986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct central effects of acute methylenedioxymethamphetamine on serotonergic neurons.
    Schmidt CJ; Taylor VL
    Eur J Pharmacol; 1988 Oct; 156(1):121-31. PubMed ID: 2463176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of flunarizine and nimodipine on the decrease in tryptophan hydroxylase activity induced by methamphetamine and 3,4-methylenedioxymethamphetamine.
    Johnson M; Mitros K; Stone DM; Zobrist R; Hanson GR; Gibb JW
    J Pharmacol Exp Ther; 1992 May; 261(2):586-91. PubMed ID: 1374469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of amphetamine-like designer drugs on monoaminergic systems in rat brain.
    Gibb JW; Stone DM; Stahl DC; Hanson GR
    NIDA Res Monogr; 1987; 76():316-21. PubMed ID: 2449619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats.
    Stone DM; Hanson GR; Gibb JW
    Neuropharmacology; 1987 Nov; 26(11):1657-61. PubMed ID: 2448703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine.
    Colado MI; Murray TK; Green AR
    Br J Pharmacol; 1993 Mar; 108(3):583-9. PubMed ID: 7682129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocorticoids and 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity.
    Johnson M; Stone DM; Bush LG; Hanson GR; Gibb JW
    Eur J Pharmacol; 1989 Feb; 161(2-3):181-8. PubMed ID: 2470597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of the acute effects of 3,4-methylenedioxymethamphetamine by 5-HT uptake inhibitors.
    Schmidt CJ; Taylor VL
    Eur J Pharmacol; 1990 May; 181(1-2):133-6. PubMed ID: 1974853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine.
    Stone DM; Johnson M; Hanson GR; Gibb JW
    J Pharmacol Exp Ther; 1988 Oct; 247(1):79-87. PubMed ID: 2902215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain.
    Stone DM; Stahl DC; Hanson GR; Gibb JW
    Eur J Pharmacol; 1986 Aug; 128(1-2):41-8. PubMed ID: 2875893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine isomers on central serotonergic, dopaminergic and nigral neurotensin systems of the rat.
    Johnson M; Letter AA; Merchant K; Hanson GR; Gibb JW
    J Pharmacol Exp Ther; 1988 Mar; 244(3):977-82. PubMed ID: 2472482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of dopamine release by methylenedioxymethamphetamine is mediated by serotonin.
    Gazzara RA; Takeda H; Cho AK; Howard SG
    Eur J Pharmacol; 1989 Sep; 168(2):209-17. PubMed ID: 2575036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine.
    Schmidt CJ; Black CK; Taylor VL
    Eur J Pharmacol; 1990 May; 181(1-2):59-70. PubMed ID: 1974858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerance and cross-tolerance to 3,4-methylenedioxymethamphetamine (MDMA), methamphetamine and methylenedioxyamphetamine.
    Zacny JP; Virus RM; Woolverton WL
    Pharmacol Biochem Behav; 1990 Mar; 35(3):637-42. PubMed ID: 1971112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the neurotoxic potential of methylenedioxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives.
    Stone DM; Johnson M; Hanson GR; Gibb JW
    Eur J Pharmacol; 1987 Feb; 134(2):245-8. PubMed ID: 2883012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of optical isomers of 3,4-methylenedioxymethamphetamine (MDMA) on stereotyped behavior in rats.
    Hiramatsu M; Nabeshima T; Kameyama T; Maeda Y; Cho AK
    Pharmacol Biochem Behav; 1989 Jun; 33(2):343-7. PubMed ID: 2573077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.